NL9201722A - Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan. - Google Patents

Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan. Download PDF

Info

Publication number
NL9201722A
NL9201722A NL9201722A NL9201722A NL9201722A NL 9201722 A NL9201722 A NL 9201722A NL 9201722 A NL9201722 A NL 9201722A NL 9201722 A NL9201722 A NL 9201722A NL 9201722 A NL9201722 A NL 9201722A
Authority
NL
Netherlands
Prior art keywords
plasminogen
liposomes
composition
activator
plasminogen activator
Prior art date
Application number
NL9201722A
Other languages
English (en)
Dutch (nl)
Original Assignee
Stichting Tech Wetenschapp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Tech Wetenschapp filed Critical Stichting Tech Wetenschapp
Priority to NL9201722A priority Critical patent/NL9201722A/nl
Priority to PCT/NL1993/000195 priority patent/WO1994007537A1/en
Priority to AU53454/94A priority patent/AU5345494A/en
Priority to CA002146324A priority patent/CA2146324A1/en
Priority to AT93923685T priority patent/ATE171073T1/de
Priority to JP6508918A priority patent/JPH08502060A/ja
Priority to DE69321131T priority patent/DE69321131D1/de
Priority to EP93923685A priority patent/EP0662841B1/en
Publication of NL9201722A publication Critical patent/NL9201722A/nl
Priority to NO951219A priority patent/NO951219L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NL9201722A 1992-10-05 1992-10-05 Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan. NL9201722A (nl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NL9201722A NL9201722A (nl) 1992-10-05 1992-10-05 Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.
PCT/NL1993/000195 WO1994007537A1 (en) 1992-10-05 1993-10-05 Pharmaceutical composition for site-specific release of a clot-dissolving protein
AU53454/94A AU5345494A (en) 1992-10-05 1993-10-05 Pharmaceutical composition for site-specific release of a clot-dissolving protein
CA002146324A CA2146324A1 (en) 1992-10-05 1993-10-05 Pharmaceutical composition for the site-specific release of clot-dissolving protein and method for the preparation thereof
AT93923685T ATE171073T1 (de) 1992-10-05 1993-10-05 Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine
JP6508918A JPH08502060A (ja) 1992-10-05 1993-10-05 血餅−溶解タンパク質の部位−特異的放出用医薬組成物
DE69321131T DE69321131D1 (de) 1992-10-05 1993-10-05 Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine
EP93923685A EP0662841B1 (en) 1992-10-05 1993-10-05 Pharmaceutical composition for site-specific release of a clot-dissolving protein
NO951219A NO951219L (no) 1992-10-05 1995-03-30 Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9201722 1992-10-05
NL9201722A NL9201722A (nl) 1992-10-05 1992-10-05 Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.

Publications (1)

Publication Number Publication Date
NL9201722A true NL9201722A (nl) 1994-05-02

Family

ID=19861342

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9201722A NL9201722A (nl) 1992-10-05 1992-10-05 Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.

Country Status (9)

Country Link
EP (1) EP0662841B1 (no)
JP (1) JPH08502060A (no)
AT (1) ATE171073T1 (no)
AU (1) AU5345494A (no)
CA (1) CA2146324A1 (no)
DE (1) DE69321131D1 (no)
NL (1) NL9201722A (no)
NO (1) NO951219L (no)
WO (1) WO1994007537A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE831867A (fr) * 1975-07-29 1976-01-29 Association d'un activateur du plasminogene, d'une part, et du plasminogene lui-meme
JPS52102975A (en) * 1976-02-24 1977-08-29 Toyota Motor Corp Hydraulic driving system
US4193983A (en) * 1978-05-16 1980-03-18 Syva Company Labeled liposome particle compositions and immunoassays therewith
CA1297791C (en) * 1985-12-16 1992-03-24 Warren Douglas Sheffield Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Also Published As

Publication number Publication date
WO1994007537A1 (en) 1994-04-14
EP0662841B1 (en) 1998-09-16
DE69321131D1 (de) 1998-10-22
CA2146324A1 (en) 1994-04-14
AU5345494A (en) 1994-04-26
ATE171073T1 (de) 1998-10-15
NO951219D0 (no) 1995-03-30
NO951219L (no) 1995-06-06
JPH08502060A (ja) 1996-03-05
EP0662841A1 (en) 1995-07-19

Similar Documents

Publication Publication Date Title
US10357448B2 (en) Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
AU725442B2 (en) A pharmaceutical preparation for treating blood coagulation disorders
Koudelka et al. Liposomal nanocarriers for plasminogen activators
US6593294B1 (en) Pharmaceutical composition comprising Factor VIII and neutral liposomes
US20090047356A1 (en) Tissue factor compositions and methods
Heeremans et al. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA
ES2449224T3 (es) Administración subcutánea del Factor de coagulación VII
Vaidya et al. Platelets directed liposomes for the delivery of streptokinase: development and characterization
US20240024430A1 (en) Synthetic platelets
MXPA03008864A (es) Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico.
Elbayoumi et al. Liposomes for targeted delivery of antithrombotic drugs
AU785103B2 (en) Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme
Moghimi et al. Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells
Kim et al. Prolonged systemic delivery of streptokinase using liposome
JP2002515447A (ja) 抑制されない血管内フィブリンクロット形成の予防および治療のための組成物および方法
Jin et al. Comparative effects of PEG-containing liposomal formulations on in vivo pharmacokinetics of streptokinase
US5658588A (en) Fibrinogen-coated liposomes
NL9201722A (nl) Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.
US20030147944A1 (en) Lipid carrier compositions with protected surface reactive functions
WO2009067407A2 (en) Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof
Gregory Liposome-Encapsulated Hemoglobin as an Artificial Oxygen Carrier
KR20240042134A (ko) A형 혈우병 치료용 변형된 콜로이드 입자
Heeremans et al. Clot accumulation characteristics of plasminogen-bearing liposomes in a flow-system
WO2023150616A1 (en) Biosynthetic hemostat and uses thereof
WO1994013323A1 (en) Method of inhibiting the clearance of liposomes from the circulation

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BV The patent application has lapsed